ED Telehealth Subscription Pricing

Direct answer

Telehealth erectile-dysfunction pricing is not one subscription model. Current RightFit data includes medication-plus-membership programs, bundled multi-month oral programs, and compounded injectable programs with clinician access and shipping included. The useful comparison therefore separates medication, formulation, strength, quantity, supply period, membership, billing cadence, and included services instead of reducing every offer to one monthly number.

Sildenafil market snapshot

Tadalafil market snapshot

Injectable ED programs

Mochi uses a medication-plus-membership structure

Mochi’s current sildenafil and tadalafil pages publish medication starting prices while requiring a separate Mochi membership. RightFit keeps the medication amount and membership as separate components so the medication price is not mistaken for the full recurring program cost.

That structure also means a future membership change can alter the practical recurring total even if the medication price remains unchanged. RightFit therefore tracks program fees separately from medication observations.

Henry’s oral ED programs use a bundled multi-month structure

Henry Meds currently publishes sildenafil and tadalafil options within a bundled ED program with longer supply periods. RightFit normalizes the source terms into effective monthly amounts for comparison while preserving the underlying supply and program structure. The normalized figure does not mean the customer is necessarily purchasing one independent month at a time.

Henry’s current oral program records also identify clinician access and shipping as included. Those features remain attached to the provider program rather than being assumed for every ED telehealth provider.

Injectable Bimix, Trimix, and Quadmix are separate compounded programs

Henry’s current catalog also includes compounded Bimix, Trimix, and Quadmix injection programs. RightFit stores those as separate treatment and formulation records rather than grouping all injectable ED products under one generic price. The current structured records use the same published monthly program amount, but identical pricing does not make the formulations identical.

These injectable programs also have a different route from sildenafil or tadalafil tablets. RightFit therefore avoids direct price-only comparisons that imply an injectable compounded product and an oral PDE5 medication are commercially or clinically interchangeable.

Official drug labels and provider program pages answer different questions

The official sildenafil and tadalafil labels establish the approved drug context for the manufactured oral medicines. Provider pages establish current telehealth pricing, quantities, memberships, and supply terms. RightFit keeps those source roles separate so a provider’s commercial page does not become the authority for approved labeling, and an official label is not used to invent a provider price.

Compounded injectable ED products require separate regulatory wording

FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. RightFit therefore does not describe compounded Bimix, Trimix, or Quadmix as FDA-approved versions of sildenafil, tadalafil, or any other approved ED medicine.

Quantity can matter as much as the normalized monthly amount

A monthly equivalent without tablet quantity or supply duration can be misleading. Henry’s current oral ED program is structured around a multi-month supply, while Mochi publishes a monthly medication amount plus membership. RightFit retains quantity and supply context so the comparison reflects what is actually purchased.

Program fee and medication price can change independently

A provider can hold a medication price steady while changing a membership fee, or change the medication amount without changing its care fee. Those are different commercial events. RightFit therefore keeps medication observations and recurring program fees in separate records and only combines them conceptually when a reader wants to understand the practical recurring obligation.

Shipping and clinician access should remain explicit

Henry’s current oral and injectable ED records identify clinician access and shipping as included in the program. Mochi’s medication records use a different model and should not inherit Henry’s inclusions. RightFit attaches each inclusion only to the provider program whose source supports it.

State availability needs program-level evidence

A telehealth company operating in many states does not automatically prove that every ED formulation it sells is available in every state. Product availability can depend on clinician licensure, pharmacy reach, formulation, and provider policy. RightFit leaves unverified state combinations blank rather than extrapolating them.

What this pricing report compares

• Exact ED medication or compounded formulation.
• Route and preparation type.
• Published strength and quantity as descriptive product fields.
• Supply duration and billing period.
• Medication or program price.
• Separate membership or recurring care fee.
• Whether clinician access and shipping are included.
• Whether the offer is oral or injectable.
• Program-level state availability when verified.
• Provider-primary source and last-verification date.

What the report does not assume

• A lower price does not establish better clinical value.
• A higher tablet strength does not establish a better program.
• A compounded injectable is not treated as an approved oral-drug equivalent.
• The same monthly price does not make Bimix, Trimix, and Quadmix interchangeable.
• A medication-only price is not treated as the full program cost when membership is required.
• A multi-month effective amount is not treated as proof of monthly billing.
• Unknown shipping, lab, or state fields are not converted to zero or nationwide availability.

Why subscription language needs care

The phrase ED subscription can describe a recurring membership, a recurring medication order, or a bundled program with a longer supply term. RightFit therefore avoids labeling every recurring ED offer as the same kind of subscription. The billing cadence and renewal structure need to be read from the provider source.

Why provider price history should track real commercial changes

A routine recheck that finds the same price should refresh verification without creating a false price-change event. A real history event belongs when the medication amount, required membership, supply quantity, bundled service, or billing term changes materially.

Questions a reader can use

• What exact medication or formulation is being offered?
• Is it manufactured or compounded?
• How many tablets, units, or doses are included?
• What supply period does the quoted amount cover?
• Is a separate membership required?
• Are clinician access and shipping included?
• Is the amount truly billed monthly or normalized from a longer term?
• Is this exact program verified in my state?
• When was the provider source last checked?

Bottom line

Current ED telehealth pricing spans medication-plus-membership offers, bundled multi-month oral programs, and compounded injectable programs. Mochi and Henry illustrate different commercial models, while Bimix, Trimix, and Quadmix add a separate compounded injectable category. RightFit keeps medication, formulation, fee, supply, and regulatory context separate so the report explains the market without ranking treatments or turning price into medical advice.

Why the same monthly amount can still represent different ED programs

Two ED programs can display the same effective monthly price while differing in product, quantity, route, and included services. Henry’s current oral and injectable program rows illustrate this: different products can share a published program amount without becoming commercially identical. RightFit therefore treats the price as one field among several rather than the sole basis for comparison.

A complete ED subscription record needs enough context to reproduce the comparison

For each program, RightFit aims to preserve the provider, medication or compounded formulation, route, supply period, quantity when published, recurring or effective monthly amount, required membership, included clinician access, shipping, source, and verification date. That makes later changes auditable and prevents a normalized monthly number from becoming detached from the provider terms that produced it.

Why a broader market report should not rank medication types

Sildenafil, tadalafil, Bimix, Trimix, and Quadmix do not become comparable treatment choices merely because they appear in the same ED market report. The index can compare public commercial structures across the category while keeping medication selection and medical appropriateness outside the ranking.

The report also keeps route and product identity visible when several ED programs share the same published price. Equal pricing is a commercial coincidence, not evidence that oral and injectable products are interchangeable or provide the same quantity, formulation, or treatment experience.